TBPH / Theravance Biopharma: YUPELRI Numbers Don't Substantiate 9x Forward Sales, Rate Hold

Theravance Biopharma has a diversified portfolio in the healthcare sector, with the potential for high returns and risk mitigation. The company's fina more_horizontal

Theravance Biopharma has pushed into congestion in 2023, backing and filling throughout the year. Its YUPELRI label offers targeted bronchodilation fo more_horizontal

DUBLIN , Aug. 28, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new amprel more_horizontal

Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year. more_horizontal

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Rick Winningham - Chief Exec more_horizontal

Theravance Biopharma (TBPH) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to more_horizontal

Theravance Biopharma has recently come under pressure from a reputable activist investor, Irenic Capital. The activist is pushing the company to initi more_horizontal

DUBLIN , April 10, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 22nd Annual Needham Virtual Healthcare Conferenc more_horizontal